• Soft·Ox Solutions - New ways of eradicating infections and fighting antimicrobial resistance.
  • Patented and clinically proven.
What are you looking for?

Press Releases & Updates

Important Press Releases & Company Updates

Regulated News

Sykehusinnkjøp HF’s national tender – hygiene products, disinfectants and dispensing solutions for hand disinfectants, soap and cream (HINAS).

SoftOx Solutions AS (SoftOx) has participated in the HINAS tender mentioned here and reports that the company’s hand disinfectant product SafeDes® has been selected and will be listed in Norwegian hospitals as the only alternative to alcohol-based products following the decision in the national tender.

From the evaluation for subcontract 16, hand disinfectants without alcohol (bottles), SoftOx received a top score on the evaluation criteria “properties on
skin” and quality. The product is an alternative for those who have skin problems related to the use of alcohol. The skin does not feel sticky or dry
after use.

This, in combination with a competitive price, is the overall evaluation that SoftOx comes out best in the assessment.

The product has been assessed by the country’s foremost professional expertise on efficacy and safety in disinfection. This is a confirmation of our base
technology, and the decision clearly shows that the product has a place in the health care system. “Winning a national hospital tender is also a very important
reference for the company in other markets, in addition to being a confirmation of our research and our work so far. This award shows that our commitment to
health has been right and provides a good basis for further investment,” says CEO Geir Almås.

The company announces increased investment in its disinfection products. Based on the clear advantages of the products: skin friendliness, effect and security,
we will continue to invest in the categories defense, health, B2B and the transportation industry. We now see that the market responds within these
categories and are experiencing increased demand and sales. However, the Norwegian hospital market is the company’s pilot customer and is not expected to
provide profitability during the first years.

With reference to the stock exchange announcement on 2 July 2021, the company is still working on the basis that company will enter a transitional arrangement in the connection with the new biocidal regulations.

Further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our vision is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com.

The first in human study of SoftOx Biofilm Eradicator started as planned at the end of May, but due to the ongoing nurses’ strike in Denmark, we do not expect
to be able to admit patients to the study until the strike is over. The strike is expected to last for approximately 10 weeks. The study is therefore expected
to be somewhat delayed; however, the company will strive to make up for lost time.

This is the phase I study with our lead wound care product, designed to treat infected chronic wounds. The study will establish a tolerable dose and treatment schedule for SBE, to be able to develop it into an effective infection-treatment solution in problematic, non-healing wounds.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Kristine M. Rød, Financial Manager of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian MedTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

With reference to the stock exchange announcement on March 29, 2021, SoftOx has now submitted a new application for national approval of its biocidal products in Norway. The application addresses the objections raised in the first application and only applies to the Norwegian market.

“The company experienced that the previous application involving Norway, Sweden and Denmark entailed great procedural complexity, which we consider to be a contributing factor to the application being rejected. The new improved application now addresses the weaknesses that were commented on in the previous application. New applications to other countries will be submitted on an ongoing basis. In addition, SoftOx has appealed the rejection of the first
application.” says CEO Geir Almås.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our vision is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com.

More information:
Access the news on Oslo Bors NewsWeb site

23 JUN 2021 11:00 CEST

SoftOx Solutions AS (SoftOx) is pleased to announce that the results of the clinical investigation SoftOx Wound Irrigation Solution for acute wounds (SWIS) have been completed. The study, which has been conducted at Bispebjerg University Hospital in Copenhagen, is a confirmatory clinical investigation to document safety and performance of SoftOx Wound Irrigation Solution (SWIS) compared to Normal Saline (NS) in a human wound model.

The study showed both significant improvement in wound healing and reduction in bacterial burden compared to Normal Saline (NS), positioning the product as superior towards today’s market leaders. Finishing the clinical development program strengthens the SoftOx platform for further product development. The results from the study “SWIS-02” confirm the excellent safety profile of the SoftOx technology platform, also strengthening the documentation of SoftOx hand disinfectant technology with regards to skin friendliness being superior to today’s alcohol-based hand disinfectant. The company now prepares to file their wound irrigation SWIS for final approval as a Medical Device in Europe.

SoftOx Wound Irrigation Solution (SWIS) will become a Medical Device intended for wound rinsing and moistening to prevent infections in all types of acute wounds, such as abrasions, cuts, burns and surgical wounds. SWIS has the potential to become a favoured alternative to the current wound irrigation solutions on the market which have challenges related to safety (side effects, resistance development) and effect. According to market reports from The Insight Partners, the global market size for wound irrigation solutions was estimated at USD 1.6 billion in 2018, and yearly 190 million wounds is treated in hospitals. Finalization of the SWIS-02 study concludes the clinical evaluation part of the SWIS documentation package. SWIS is expected to be the company’s first CE-marked product for the European market.
Regarding the wound healing capabilities, the study meets its primary endpoint of re-epithelialization (non-inferior to NS) by day 10 with high significance (p<0.0001). Furthermore, early re-epithelialization at day 4 was significantly better than normal saline (mean 57% versus 43%, p<0.0001). Also, overall usability aspects of SWIS handling were reported to be satisfactory.

Once again SWIS demonstrates and confirms previous findings (from SWIS-01) to be safe and well tolerated as a wound irrigation solution for acute wounds and not associated with any major risks. Performance outcomes demonstrate antimicrobial properties with excellent wound healing (re-epithelialization) observations. “This has been a highly successful study with respect to implementation, conduct and outcome and clearly confirms the favourable properties of SWIS as an excellent wound irrigation solution,” says Glenn Gundersen, Medical Director of SoftOx.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, Medical Director of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our vision is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com.

More information:
Access the news on Oslo Bors NewsWeb site

07 JUN 2021 07:00 CEST

SoftOx Solutions AS (SoftOx) aims to develop an inhalation solution (SIS) for the treatment of respiratory tract infections. This has the potential to be a breakthrough in the future treatment of respiratory infections, including viruses, bacteria and fungal infections.

“After an intensive research phase, we are very satisfied that the Danish Medicines Agency (DKMA) considers our documentation positively and has given a conditional approval to be able to start the study”, says Medical Director Glenn Gundersen. “The conditions that have been communicated are related to additional safety data and the company is already working on completing the data as requested. The data will be provided in due time and we believe that the study can be initiated during the autumn.”

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, Medical Director in SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our Vison is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com.

More information:
Access the news on Oslo Bors NewsWeb site

26 APR 2021 13:58 CEST

In connection with SoftOx Solutions AS reporting for the first quarter of 2021, SpareBank 1 Markets invites to a presentation with the company on Thursday 29 April at 1400.

Date: Thursday 29 April
Time: 14:00 – 15:00
RSVP: Registration to corporateaccess@sb1markets.no

More information:
Access the news on Oslo Bors NewsWeb site

13 APR 2021 19:46 CEST

Det ble avholdt en ordinær generalforsamling i SoftOx Solutions AS den 13. april 2021 kl. 09.00. På grunn av gjeldende restriksjoner mot innendørs arrangementer i Oslo kommune som følge av Covid-19, ble generalforsamlingen kun avholdet som elektronisk møte. 2 671 336 aksjer var representert, tilsvarende 29,14 % av selskapets totale aksjekapital.

Generalforsamlingen vedtok alle forslagene på agendaen i tråd med innkallingen datert 6. april 2021.

Signert protokoll fra generalforsamlingen er vedlagt denne meldingen og vil bli gjort tilgjengelig på selskapets hjemmeside.

More information:
Access the news on Oslo Bors NewsWeb site

09 APR 2021 08:00 CEST

The National Committee of Health Research Ethics (NVK) in Denmark has approved the “SBE-01 study”, a first-in-human, phase I clinical trial in patients with chronic wounds. The study has now received full regulatory clearance to make the
final preparations for initiation. Reference is made to the previous stock announcement of 15th March 2021 regarding authorisation from the Danish Medicines Agency.

“This rapid approval by the relevant regulatory bodies in Denmark will enable us to start the study during Q2-2021” says Glenn Gundersen, Medical Director in SoftOx Solutions.

SBE-01: EudraCT no. 2021-000314-42.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, Medical Director of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our Vison is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working
to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

06 APR 2021 09:00 CEST

SoftOx Solutions AS will be holding its Annual General Meeting [virtually] on 13 April 2021 at 09:00 hours (CET).

The notice, registration form and power of attorney are attached to this release. The notice will be sent to all registered shareholders and is available on the Company’s website: https://soft-ox.com/.

All shareholders are encouraged to exercise their shareholder rights, either by using the enclosed proxy form to provide proxy to the Chairman Melvin Teigen (or the person he appoints), or to attend the general meeting virtually.

Shareholders who wish to participate electronically must register using the attached notice of attendance in order to receive a link to the general meeting. The notice of attendance and proxy form must be received prior to 12 April 2021 at 15:00. Notice of attendance and proxy form are attached to this notice.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Kristine Rød, FM in SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our Vison is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working to combat major threats to human health, namely the emergence of antimicrobial
resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

29 MAR 2021 14:32 CEST

With reference to the stock exchange announcement from SoftOx Solutions AS (“SoftOx”) on December 11th, 2020, when SoftOx received information from the Swedish Chemicals Agency that the application for SoftOx Disinfection Products was sufficiently complete to proceed to the final decision-making. Contrary to
this statement, the Swedish Chemicals Agency changed its initial position by rejecting SoftOx application with reference to its latest request for additional testing data.

This implies an estimated six-months delay for SoftOx’s major launch in the European markets, notwithstanding, the Swedish decision does not affect continued sales and marketing in Norway, Sweden and Denmark.

“Based on the information received in December we were confident that our data was sufficient to approve our products. We are surprised by the decision and the justification when the Agency now ask for additional tests”, says CEO Geir Almås of SoftOx Solutions AS.

The request for additional test concerns certain impurities in the formulated disinfectants. SoftOx fundamentally and scientifically disagrees with the Swedish Chemicals Agency’s assessment and request for additional tests for this data. During the evaluation process, SoftOx submitted a series of test data, generated by the accredited third-party laboratory “Sintef”, in which it was confirmed that the concerned impurities does not impact adversely the SoftOx disinfectant products. In support of this, SoftOx has also undertaken additional tests to verify its initial conclusions presented to the competent authorities during the evaluation process. These confirmatory tests (including requested tests) are anticipated to be finalized in November 2021.

Notwithstanding, SoftOx is committed to defend its scientific position and pursue its biocides submission before the national competent authorities. On advice from its scientific experts, SoftOx intends to contest and submit an administrative appeal in Sweden, and to undertake additional regulatory measures to ensure a scientifically viable and sustainable implementation of EU’s biocides regime on SoftOx products.

“SoftOx feels confident that when the requested documentation is available, the application will be duly recognized.” Says Almås.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our Vision is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com.

More information:
Access the news on Oslo Bors NewsWeb site

23 MAR 2021 15:49 CET

SoftOx Solutions AS (“SoftOx”) is pleased to announce that the enrolment of study participants for the clinical investigation «SWIS-02» has been completed. The study, which has been conducted at Bispebjerg University Hospital is a confirmatory clinical investigation to document safety and performance of SoftOx Wound Irrigation Solution (“SWIS”) compared to Normal Saline (NS) in a human wound model. It is a confirmative study and last of two clinical studies on “SWIS”.

We are very pleased to have completed this enrolment because of the ongoing lockdown in Denmark, which were affecting our recruitment pace. “With this pivotal trial we are eagerly looking forward to examining and analyse the study data and report on the results later in Q2-2021”, says Glenn Gundersen, Medical Director of SoftOx.

SWIS is under development to become a medical device intended for wound rinsing and moistening to prevent infections in all types of acute wounds, such as abrasions, cuts, burns and surgical wounds.

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Glenn Gundersen, Medical Director in SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our Vison is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance”. We are working to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

22 MAR 2021 08:30 CET

Reference is made to the stock exchange announcement from SoftOx Solutions AS (SoftOx) on 3rd February 2021 regarding the signing of a letter of intent, the collaboration agreement has now been finalized. SoftOx and the Norwegian Defense Research Establishment (FFI) have signed a collaboration agreement that extends until June 30th 2024. The main focus of the agreement will be on adapting the technology and products the company develops for military purposes both nationally and internationally.

SoftOx is developing a new class of antimicrobial agents, herunder range of wound care products for cleansing, prevention and treatment of wound infections, as well as a product for the treatment of respiratory tract infections. Currently the company delivers alcohol-free hand and surface disinfection products with a broader effect and more unique properties than current products on the market.

The parties have a joint vision to further develop the SoftOx applications to strengthen the military and civilian preparedness against future epidemics, chemical and biological warfare, complexed wound infections and challenging conditions in the respiratory tract.

The plan is to develop a range of military SoftOx products that will be specifically targeted for the needs of the Armed Forces and for civilian purposes in conflict areas. This work will take place in close collaboration with both our national and international civilian and military partners.

“We express high expectations for this collaboration, and we appreciate that FFI has chosen to enter into a collaboration with us. Together we will be improve the safety and the preparedness of our armed forces. We also believe that this agreement will contribute to our products becoming part of the national preparedness in the fight against infections and multi-resistant bacterias, “says CEO Geir Almås in SoftOx Solutions.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or
Rune Jomaas, Project Director SoftOx Solutions AS.
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

About Norwegian Defense Research Establishment Norwegian Defence Research Establishment (FFI) is the prime institution responsible for defence-related research in Norway. The Establishment is the chief adviser on defence-related science and technology to the Ministry of
Defence and the Norwegian Armed Forces’ military organization. The demand for expert and flexible armed forces requires continuous renewal and Norway’s unflagging emphasize on defence technology keeps FFI busy. It is a true challenge to make significant contributions to the development of the Armed Forces – both in its principal national defence role as well as in its various roles as an effective participant in international security operations. Relevant defence research now requires international cooperation. In order to maintain a position at the forefront of science and technology within chosen sectors, FFI collaborates with national and international scientific institutions and industry. The Establishment also has a close working relationship with its partners and customers (Sourse www.ffi.no)

About SoftOx Solutions AS
SoftOx Solutions AS is a Norwegian BioTech company listed on Euronext Growth Oslo. Our Vison is “Helping the world fighting infections – developing new ways of eradicating infections and fighting antimicrobial resistance” We are working to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

04 MAR 2021 12:28 CET

Reference is made to the stock exchange announcement from SoftOx Solutions AS (the “Company”) on 3 March 2021 regarding the preliminary results of the Company’s Subsequent Offering.

The final results confirms the preliminary results reported yesterday. As a result, the Company has received valid subscriptions for in total 971,404 Offer Shares. Hence, the maximum number offered in the Subsequent Offering (181,818 offer shares) will be issued.

The allocation of the offer shares has today been completed based on the allocation criteria set out in the Company’s national prospectus dated 15 February 2021.

Notification of allocated offer shares and the corresponding amount to be paid by each subscriber will be set out in a separate letter to each subscriber, which is expected to be issued during the course of today, 4 March 2021. The payment date for the offer shares allocated is 8 March 2021 and the shares is to be paid for in accordance with the payment instructions set out in the national prospectus and subscription form.

The offer shares may not be transferred or traded until they are fully paid and the share capital increase related to the subsequent offering has been registered with Norwegian Register of Business Enterprises (Nw: Foretaksregisteret). The share capital increase is expected to be registered on or about 12 March 2021. The Offer Shares are expected to be delivered to the subscribers’ respective VPS accounts on or about the 15 March, and be tradeable on Euronext Growth Oslo on or about 16 March 2021.

Following the issuance of the offer shares issued in the Subsequent Offering and the offer shares issued in the employee offering on 24 February 2021, the Company’s share capital will be NOK 183,369.36 divided into 9,168,468 shares, each with a par value of NOK 0.02. See the attached form for notification and publication of allocation to primary insiders.

SpareBank 1 Markets AS has acted as Manager and Advokatfirmaet Wiersholm AS has acted as legal advisor to as the Company in connection with the Subsequent Offering.

For further information, please contact: Geir Almås, CEO of SoftOx Solutions AS, or Kristine Rød, FM of SoftOx Solutions AS

Mail: ir@soft-ox.com
Mobile: +47 977 59 071

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian MedTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

03 MAR 2021 20:00 CET

Reference is made to the stock exchange announcement from SoftOx Solutions AS (the “Company”) on 16 February 2021 regarding the commencement of the subscription period in the subsequent offering of up to 181,818 new shares at a subscription price of NOK 55 per offer share directed towards eligible shareholders as of 16 December 2020 (as registered in the VPS on 18 December 2020) who did not participate in the private placement successfully completed on the 16 December 2020 (the “Subsequent Offering”).

The subscription period for the Subsequent Offering expired at 16:30 hours (CEST) today, 3 March 2021. Preliminary counting indicates that the Company has received subscriptions for approximately 971 404 offer shares. The final allocation of the offer shares is expected to take place on or about 4 March 2021, in accordance with the allocation criteria set out in the national prospectus.

The final results of the Subsequent Offering will be published shortly after allocation, and letters with allocation information including subscription amount to be paid by each subscriber are expected to be distributed during the course of 4 March 2021.

The payment date for the offer shares allocated in the Subsequent Offering is 8 March 2021, and the delivery date for such shares is expected to be on or about 15 March 2021. The offer shares allocated in the Subsequent Offering are expected to be tradeable on Euronext Growth Oslo on or about 16 March 2021.

SpareBank 1 Markets AS has acted as Manager and Advokatfirmaet Wiersholm AS has acted as legal advisor to as the Company in connection with the Subsequent Offering.

For further information, please contact: Geir Almås, CEO of SoftOx Solutions AS, or Kristine Rød, FM of SoftOx Solutions AS

Mail: ir@soft-ox.com

Mobile: +47 977 59 071

About SoftOx Solutions AS

SoftOx Solutions AS (SoftOx, listed on the Oslo Stock Exchange Euronext Growth) is a Norwegian MedTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

03 MAR 2021 08:00 CET

Reference is made to the stock exchange announcement from SoftOx Solutions AS (the “Company”) on 16 February 2021 regarding the commencement of the subscription period in the subsequent offering of up to 181,818 new shares at a subscription price of NOK 55 per offer share directed towards eligible shareholders as of 16 December 2020 (as registered in the VPS on 18 December 2020) who did not participate in the private placement successfully completed on the 16 December 2020 (the “Subsequent Offering”).

The subscription period for the Subsequent Offering will expire today, on 3 March 2021 at 16:30 (CEST). In order to subscribe for offer shares, SpareBank 1 Markets AS (the “Manager”) must receive a complete and duly signed subscription form within 16:30 today.

Subscription rights that are not used to subscribe for offer shares before the expiry of the subscription period will have no value and will lapse without compensation to the holder.

For further information, please refer to the national prospectus available on the Company’s website www.soft-ox.com, the Manager’s website www.sb1markets.no and that may be ordered from the Norwegian Register of Business Enterprises (Nw: Foretaksregisteret).

For further information, please contact:

Geir Almås, CEO of SoftOx Solutions AS, or
Kristine Rød, FM of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: +47 977 59 071

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian MedTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

01 MAR 2021 10:37 CET

Reference is made to the stock exchange announcement from SoftOx Solutions AS (the “Company”) on 16 February 2021 regarding the employee offering.

The Board of Directors has resolved to issue a total of 164,348 new shares, each with a nominal value of NOK 0.02, to employees who had applied for shares. The shares were issued under a board authorization granted by the Company’s general meeting on 4 January 2021.

The new shares were issued at a subscription price of NOK 55, resulting in gross proceeds of approx. NOK 9,039,140. The following primary insiders subscribed and were allocated shares in the Employee Offering:

– Melvin Teigen (chairman) has subscribed for 10,000 shares at a subscription price of NOK 55 per offer share in the Employee Offering. Following the subscription, Teigen holds 16,000 shares in the Company.

– Geir Almås (CEO) has, through his holding company Hermod Farms AS, subscribed for 36,360 shares at a subscription price of NOK 55 per offer share in the Employee Offering. Following the subscription, Almås together with his close associates holds 861 473 shares in the Company.

– Kristine Rød (CFO) has subscribed for 3,637 shares at a subscription price of NOK 55 per offer share in the Employee Offering. Following the subscription, Rød holds 3,637 shares in the Company.

– Primary insider Hans Petter Grette has, through his holding company Renholdsprodukter AS, subscribed for 7,288 shares at a subscription price of NOK 55 per offer share in the Employee Offering. Following the subscription, Grette together with his close associates holds 90,000 shares in the Company.

– Primary insider Glenn Gundersen has subscribed for 4,550 shares at a subscription price of NOK 55 per offer share in the Employee Offering. Following the subscription, Gundersen holds 10,550 shares in the Company.

– Primary insider Elisabeth Ahlmann Ohlsen has subscribed for 200 shares at a subscription price of NOK 55 per offer share in the Employee Offering. Following the subscription, Ohlsen holds 200 shares in the Company.

– Primary insider Dag Abrahamsen has, through his holding company Genesis Holding AS, subscribed for 3,636 shares at a subscription price of NOK 55 per offer share in the Employee Offering. Following the subscription, Abrahamsen holds 3,636 shares in the Company.

The shares will be delivered through VPS and will be admitted to trading on Euronext Growth Oslo following the registration of the shares in the Norwegian Register of Business Enterprises (Nw: Foretaksregisteret).

This announcement is made under the Norwegian Securities Trading Act Section 4-2.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS, or Kristine Rød, FM of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: +47 977 59 071

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian MedTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site

25 FEB 2021 18:38 CET

Reference is made to the stock exchange announcement from SoftOx Solutions AS (the “Company”) on 16 February 2021 regarding the commencement of the subscription period in the planned subsequent offering and parallel employee offering, both consisting of an issuance of up to 181,818 new shares in the Company (the “Subsequent Offering”) (the “Employee Offering”).

Primary insider Claus Seeberg, though his holding company CS Holding AS has committed to subscribe for NOK 293 150 in the Subsequent Offering.

The shares in the Subsequent offering will be allocated by the Board of Directors and issued under a board authorization granted by the Company’s general meeting held on 4 January 2021. The shares in the Subsequent Offering will be allocated by the Board of Directors and will be issued in accordance with the resolution made by the Company’s general meeting held on 4 January 2021.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS
Kristine Rød, FM of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: +47 977 59 071

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on the Oslo Stock Exchange Euronext Growth) is a Norwegian MedTech company based in Oslo with the aim of helping to combat major threats to human health, namely the emergence of antimicrobial resistance (AMR), biofilm infections in chronic wounds and the spread of viruses. For more information on SoftOx, visit www.soft-ox.com

More information:
Access the news on Oslo Bors NewsWeb site